# Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

> **NCT02414854** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 1902 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Inhaled corticosteroid (ICS) therapy
- **DRUG:** Albuterol/Salbutamol
- **DRUG:** Levalbuterol/Levosalbutamol

## Key facts

- **NCT ID:** NCT02414854
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-27
- **Primary completion:** 2017-07-29
- **Final completion:** 2017-11-23
- **Target enrollment:** 1902 (ACTUAL)
- **Last updated:** 2018-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414854, "Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02414854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*